The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Open accessAbstract
BACKGROUND: Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression. METHODS: In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score. RESULTS: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet velocity were 0.199+/-0.210 m per second per year in the atorvastatin group and 0.203+/-0.208 m per second per year in the placebo group (P=0.95; adjusted mean difference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year). Progression in valvular calcification was 22.3+/-21.0 percent per year in the atorvastatin group, and 21.7+/-19.8 percent per year in the placebo group (P=0.93; ratio of post-treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to 1.050). CONCLUSIONS: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression. This study cannot exclude a small reduction in the rate of disease progression or a significant reduction in major clinical end points. Long-term, large-scale, randomized, controlled trials are needed to establish the role of statin therapy in patients with calcific aortic stenosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several randomized trials showed no effect of statins on haemodynamic progression or AS-related clinical events152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three randomized clinical trials (RCTs) failed to demonstrate any significant benefit of LDL lowering with statins on the progression of AS152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Several intervention studies have been performed to test the hypothesis that lipid lowering with statin medications would slow the progression of AS, however the results were generally disappointing152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“randomized controlled trials (RCTs) failed to demonstrate any benefit of statin therapy on retard disease progression6–8.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Several clinical trials evaluating statin therapy in mild to moderate AS failed to demonstrate efficacy in lipid lowering as a strategy to mitigate adverse events in the disease39–41.”
From Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction (2026) · cites this paper as [39]
In the citing paper
“lipid-lowering therapy to delay progression of AS has been evaluated in 3 randomized controlled trials; however, all trials reported no significant benefit.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“The SALTIRE (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression) and ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trials, which evaluated statin efficacy in AS, were constrained by small sample sizes (n=150 and n=269), 12,13 limited median follow-up periods (25 and 42 months), and a focus on advanced AS stages (mean peak velocity, 3.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“All of the clinical trials aimed to halt the progression of established AS.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Second, we observed similar associations with AVR as a strict procedural outcome, which is particularly meaningful in the context of previous neutral clinical trials of lipid-lowering therapies that used AVR as the study end point.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12% per mmol/L reduction in LDL cholesterol), MI, and vascular death [459,460].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [459]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Suggestions for an association between aortic stenosis, LDL-C and Lp(a), as well as between cholesterol and increased risk for calcification of bioprosthetic valves, were matched with early observational noncontrolled trials that showed beneficial effects of aggressive lipid lowering in slowing the progression of aortic stenosis. However, this was not confirmed in RCTs. 243,377,378”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Zoghbi, W. A., Enriquez-Sarano, M. L., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quiñones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,041
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis
Rosenhek, R., Binder, T. M., Porenta, G., Lang, I. M., Christ, G., SCHEMPER, M., Maurer, G., & Baumgartner, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430903 · Cited by 1,332
Otto, C. M., Kuusisto, J., Reichenbach, D. D., Gown, A. M., & O’Brien, K. D. (1994) · Circulation · doi:10.1161/01.cir.90.2.844 · Cited by 1,315
Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly
Otto, C. M., Lind, B. K., Kitzman, D. W., Gersh, B. J., & Siscovick, D. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410302 · Cited by 1,281
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,000
Progressive Aortic Stenosis in Homozygous Familial Hypercholesterolemia After Liver Transplant
Greco, M., Robinson, J. D., Eltayeb, O. M., & Benuck, I. (2016) · PEDIATRICS · doi:10.1542/peds.2016-0740 · Cited by 27
Congenital aortic stenosis in adults: Rate of progression and predictors of clinical outcome
Yap, S., Kouwenhoven, G. C., Takkenberg, J. J. M., Galema, T. W., Meijboom, F. J., van Domburg, R., Simoons, M. L., & Roos‐Hesselink, J. W. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.11.092 · Cited by 27
APOE alleles are not associated with calcific aortic stenosis
Ortlepp, J. R., Pillich, M., Mevissen, V., Krantz, C., Kimmel, M., Autschbach, R., Langebartels, G., Erdmann, J., Hoffmann, R., & Zerres, K. (2006) · Heart · doi:10.1136/hrt.2005.075317 · Cited by 27
Aortic stenosis at young adult age
Yap, S., Takkenberg, J. J. M., Witsenburg, M., Meijboom, F. J., & Roos‐Hesselink, J. W. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.6.1087 · Cited by 27
Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis
Rämö, J. T., Jurgens, S. J., Kany, S., Choi, S. H., Wang, X., Smirnov, A. N., Friedman, S. F., Maddah, M., Khurshid, S., Ellinor, P. T., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070982 · Cited by 26
Pravastatin and Olmesartan Synergistically Ameliorate Renal Failure-Induced Vascular Calcification
Iijima, K., Ito, Y., Son, B., Akishita, M., & Ouchi, Y. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.23218 · Cited by 26
Diederichsen, A. C. P., Lindholt, J. S., Møller, J. E., Gerke, O., Rasmussen, L. M., & Dahl, J. S. (2022) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.013165 · Cited by 26
Beigel, R., & Beigel, Y. (2009) · Journal of Clinical Apheresis · doi:10.1002/jca.20215 · Cited by 26
Aortic Stenosis: Pathophysiology, Diagnosis, and Medical Management of Nonsurgical Patients
Cary, T., & Pearce, J. (2013) · Critical Care Nurse · doi:10.4037/ccn2013820 · Cited by 26
Update on rheumatic heart disease
Yanagawa, B., BUTANY, J. W., & Verma, S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000269 · Cited by 26
Deng, G., Zhang, L.-Y., Wang, C., Wang, S., Xu, J., Dong, J., Kang, Q., Zhai, X., Zhao, Y., & Shan, Z. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111088 · Cited by 26
Leskelä, H., Satta, J., Oiva, J., Eriksen, H. A., Risteli, J., Korkiamäki, P., Ivaska, K. K., Soini, Y., & Lehenkari, P. P. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.07.014 · Cited by 29
Molecular Basis of Cardiovascular Disease
Liu, C. A., & Gotlieb, A. I. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374419-7.00014-7 · Cited by 26
Is it Time for a New Paradigm in Calcific Aortic Valve Disease?
Owens, D. S., & Otto, C. M. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2009.02.016 · Cited by 26
Bouchareb, R., Côté, N., Marie-Chloé-Boulanger, Le Quang, K., El Husseini, D., Asselin, J., Hadji, F., Lachance, D., Shayhidin, E. E., Mahmut, A., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.03.002 · Cited by 25
One problem two issues! Left ventricular systolic and diastolic dysfunction in aortic stenosis.
Elahi, M. M., Chuang, A., Ewing, M. J., Choi, C. H., Grant, P. W., & Matata, B. M. (2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2013.06.05 · Cited by 25
The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups
Catapano, A. L., Toth, P. P., Tomassini, J. E., & Tershakovec, A. M. (2013) · Clinical Lipidology · doi:10.2217/clp.12.88 · Cited by 26
Statins stimulate RGS-regulated ERK 1/2 activation in human calcified and stenotic aortic valves
Anger, T., El-Chafchak, J., Habib, A., Stumpf, C., Weyand, M., Daniel, W. G., Hombach, V., Hoeher, M., & Garlichs, C. D. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.06.002 · Cited by 25
Gkizas, S., Koumoundourou, D., Sirinian, X., Rokidi, S. G., Mavrilas, D., Koutsoukos, P. G., Papalois, A. E., Apostolakis, E. E., Alexopoulos, D. K., & Papadaki, H. H. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.048 · Cited by 25
Pathophysiology of Aortic Stenosis and Mitral Regurgitation
Perrucci, G. L., Zanobini, M., Gripari, P., Songia, P., Alshaikh, B. A., Tremoli, E., & Poggio, P. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160020 · Cited by 25
KPT-330 Prevents Aortic Valve Calcification via a Novel C/EBPβ Signaling Pathway
Dutta, P., Kodigepalli, K. M., LaHaye, S., Thompson, J. W., Rains, S., Nagel, C., Thatcher, K., Hinton, R. B., & Lincoln, J. (2021) · Circulation Research · doi:10.1161/circresaha.120.318503 · Cited by 24
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 24
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 25
Calcific Aortic Valve Disease: New Concepts
Otto, C. M. (2010) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2011.01.009 · Cited by 24
Afşar, Ç. U., Uzun, H., Yurdakul, S., Müderrisoğlu, C., Ergüney, M., Demir, B., Aslan, A., Aral, H., & Özyazgan, S. (2012) · Clinical and investigative medicine · doi:10.25011/cim.v35i4.17149 · Cited by 24
Osranek, M., Pilip, A., Patel, P. R., Molisse, T., Tunick, P. A., & Kronzon, I. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.026 · Cited by 24
A time course investigation of the statin paradox among valvular interstitial cell phenotypes
Monzack, E. L., & Masters, K. S. B. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00263.2012 · Cited by 25
Tastet, L. L., Capoulade, R., Shen, M., Clavel, M.-A. A., Côté, N., Mathieu, P., Arsenault, M., Bédard, É., Tremblay, A., Samson, M., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007980 · Cited by 25
Degenerative Aortic Stenosis, Dyslipidemia and Possibilities of Medical Treatment
Kleinauskienė, R., & Jonkaitienė, R. (2018) · Medicina · doi:10.3390/medicina54020024 · Cited by 25
Zhang, W., Rossini, G., Kamensky, D., Bui–Thanh, T., & Sacks, M. S. (2021) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.3438 · Cited by 24
Valvular Aortic Stenosis in the Elderly
Aronow, W. S. (2007) · Cardiology in Review · doi:10.1097/crd.0b013e31805f6796 · Cited by 24
Premature Valvular Heart Disease in Homozygous Familial Hypercholesterolemia
Fahed, A. C., Shibbani, K., Andary, R. R., Arabi, M. T., Habib, R., Nguyen, D. D., Haddad, F., Moubarak, E. M., Nemer, G. M., Azar, S. T., et al. (2017) · Cholesterol · doi:10.1155/2017/3685265 · Cited by 24
The Pathogenesis and Treatment of the Valvulopathy of Aortic Stenosis: Beyond the SEAS
Elmariah, S., & Mohler, E. R. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0089-6 · Cited by 23
Finegold, J. A., Manisty, C., Cecaro, F., Sutaria, N., Mayet, J., & Francis, D. P. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.04.105 · Cited by 23
Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease
Aronow, W. S., & Frishman, W. H. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181c29571 · Cited by 23
Low-density lipoprotein and aortic stenosis
Rajamannan, N. M. (2008) · Heart · doi:10.1136/hrt.2007.130971 · Cited by 23
Hoshina, M., Wada, H., Sakakura, K., Kubo, N., Ikeda, N., Sugawara, Y., Yasu, T., Ako, J., & Momomura, S. (2011) · Journal of Cardiology · doi:10.1016/j.jjcc.2011.10.003 · Cited by 23
van Driel, B., Schuldt, M., Algül, S., Levin, E., Güçlü, A., Germans, T., van Rossum, A. C., Pei, J., Harakaľová, M., Baas, A. F., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073569 · Cited by 23
Proceedings of the TCT: Balloon Aortic Valvuloplasty Appropriate for Elderly Valve Patients
Feldman, T. E. (2006) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2006.00143.x · Cited by 23
Aortic sclerosis, aortic stenosis and lipid-lowering therapy
Rosenhek, R., & Baumgartner, H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.385 · Cited by 23
The Causal-Benefit Model to Prevent Cardiovascular Events
Kohli-Lynch, C. N., Thanassoulis, G., Pencina, M. J., Sehayek, D., Pencina, K. M., Moran, A. E., & Sniderman, A. D. (2024) · JACC Advances · doi:10.1016/j.jacadv.2023.100825 · Cited by 23
Hénaut, L., Candellier, A., Huish, S., Issa, N., Sinha, S., & Massy, Z. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae421 · Cited by 22
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 24
Atorvastatin Attenuates Bone Loss and Aortic Valve Atheroma in LDLR-/- Mice
Rajamannan, N. M. (2015) · Cardiology · doi:10.1159/000381703 · Cited by 22
Yasuhara, J., Schultz, K. B., Bigelow, A. M., & Garg, V. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1142707 · Cited by 25
Closed heart surgery: Back to the future
Lichtenstein, S. V. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.01.025 · Cited by 22
Aortic Stenosis: A Contemporary Review
Sawaya, F., Liff, D. A., Stewart, J. T., Lerakis, S., Babaliaros, V. C., & Lerakis, S. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3182539d70 · Cited by 22
Suihko, S., Laine, M., Lommi, J., Kaartinen, M., Werkkala, K., Kovanen, P. T., & Kupari, M. M. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000182 · Cited by 22
Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?
Rajamannan, N. M., Antonini‐Canterin, F., Moura, L. M., Zamorano, J. L., Rosenhek, R., Best, P. J. M., Lloyd, M. A., Rocha‐Gonçalves, F., Chandra, S., Alfieri, O., et al. (2009) · PubMed · Cited by 22
Anger, T., Carson, W., Weyand, M., Daniel, W. G., Hoeher, M., & Garlichs, C. D. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.11.001 · Cited by 22
Venema, C. S., van Bergeijk, K. H., Hadjicharalambous, D., Andreou, T., Tromp, J., Staal, L., Krikken, J. A., van der Werf, H. W., van den Heuvel, A. F. M., Douglas, Y. L., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100879 · Cited by 21
Jneid, H. M., Chikwe, J., Arnold, S. V., Bonow, R. O., Bradley, S. M., Chen, E. P., Diekemper, R. L., Fugar, S., Johnston, D. R., Kumbhani, D. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.006 · Cited by 21
Zigelman, C. Z., & Edelstein, P. M. (2009) · Anesthesiology Clinics · doi:10.1016/j.anclin.2009.07.012 · Cited by 21
Prevention of aortic valve stenosis: A realistic therapeutic target?
Ngo, D. T. M., Sverdlov, A. L., & Horowitz, J. D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.001 · Cited by 21
Prevention of calcific aortic valve stenosis—fact or fiction?
Cawley, P. J., & Otto, C. M. (2008) · Annals of Medicine · doi:10.1080/07853890802331394 · Cited by 21
Yamamoto, K., Koretsune, Y., Akasaka, T., Kisanuki, A., Ohte, N., Takenaka, T., Takeuchi, M., Yoshida, K., Iwade, K., Okuyama, Y., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.10.027 · Cited by 21
Anselmo, W., Branchetti, E., Grau, J. B., Li, G., Ayoub, S., Lai, E. K., Rioux, N., Tovmasyan, A. G., Fortier, J. H., Sacks, M. S., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007861 · Cited by 21
Kontogeorgos, S., Thunström, E. Ö., Basic, C., Hansson, P., Zhong, Y., Ergatoudes, C., Morales, D. L. S., Mandalenakis, Z., Rosengren, A., Caidahl, K., et al. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1685126 · Cited by 21
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing
Youssef, A., Clark, J. R., Koschinsky, M. L., & Boffa, M. B. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.001 · Cited by 21
Association between asymptomatic carotid atherosclerosis and degenerative aortic stenosis
Novo, G., Guarneri, F. P., Ferro, G., Russo, R., Fattouch, K., & Novo, S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.06.011 · Cited by 21
Wakabayashi, K., Tsujino, T., Naito, Y., Ezumi, A., Lee‐Kawabata, M., Nakao, S., Goda, A., Sakata, Y., Yamamoto, K., Daimon, T., et al. (2010) · Heart and Vessels · doi:10.1007/s00380-010-0052-x · Cited by 21
Pathology of Calcific Aortic Stenosis
Ladich, E. R., Nakano, M., Carter‐Monroe, N., & Virmani, R. (2011) · Future Cardiology · doi:10.2217/fca.11.53 · Cited by 21
Hermans, H., Herijgers, P., Holvoet, P., Verbeken, E. V., Meuris, B., Flameng, W. J., & Herregods, M. (2010) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2010.02.002 · Cited by 23
Remnant cholesterol and the risk of aortic valve calcium progression: insights from the MESA study
Li, Z., Hao, Q.-Y., Zeng, Y. H., Guo, J., Li, S., Gao, J., & Yang, P. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02081-2 · Cited by 20
Lee, S. H., & Choi, J. (2018) · Animal Cells and Systems · doi:10.1080/19768354.2018.1528175 · Cited by 20
Lee, S., Sung, J. M., Andreini, D., Al-Mallah, M. H., Budoff, M. J., Cademartiri, F., Chinnaiyan, K. M., Choi, J. H., Chun, E. J., Conte, E., et al. (2021) · Radiology · doi:10.1148/radiol.2021202630 · Cited by 20
Calcific and Degenerative Heart Valve Disease
Aïkawa, E., & Schöen, F. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405206-2.00009-0 · Cited by 23
Coffey, S., D’Arcy, J. L., Loudon, M. A., Mant, D., Farmer, A. A., Prendergast, B., & for the OxVALVE-PCS group (2014) · Open Heart · doi:10.1136/openhrt-2014-000043 · Cited by 20
Abdominal obesity and the metabolic syndrome: A surgeon's perspective
Mathieu, P. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)71045-6 · Cited by 20
Rethinking Audit and Inspection
Rustin, M. (2004) · Soundings · doi:10.3898/136266204820467328 · Cited by 20
Moderate aortic stenosis: culprit or bystander?
Pankayatselvan, V., Raber, I., Playford, D. A., Stewart, S., Strange, G. A., & Strom, J. B. (2022) · Open Heart · doi:10.1136/openhrt-2021-001743 · Cited by 19
Evangelista, A., Galián-Gay, L., Guala, A., Teixidó‐Turà, G., Calvo, F., Sevilla, T., Bermejo, J., Méndez, I., Sánchez, V., Carmona, J. M. R., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067537 · Cited by 19
Ellis, S. G., Dushman-Ellis, S., Luke, M. M., Murugesan, G., Kottke‐Marchant, K., Ellis, G. M., Griffin, B. P., Tuzcu, E. M., & Hazen, S. L. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.053 · Cited by 19
Animal models of organic heart valve disease
Roosens, B., Bala, G., Droogmans, S., Camp, G. V., Breyne, J., & Cosyns, B. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.065 · Cited by 19
Aortic stenosis: a general overview of clinical, pathophysiological and therapeutic aspects
Akerström, F. O., Barderas, M. G., & Padial, L. R. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.171 · Cited by 19
Dimitrow, P. P., Jawień, M., & Gackowski, A. (2011) · PubMed · Cited by 19
Doerner, J., Kupczyk, P. A., Wilsing, M., Luetkens, J. A., Storm, K., Fimmers, R., Hickethier, T., Eichhorn, L., Naehle, C. P., Schild, H. H., et al. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27122 · Cited by 19
Durability of transcatheter aortic valve implantation: A translational review
Fauvel, C., Capoulade, R., Durand, É., Béziau, D. M., Schott, J., Tourneau, T. L., & Eltchaninoff, H. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.11.007 · Cited by 20
Loomba, R. S., & Arora, R. R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181a2b1a6 · Cited by 19
Statin treatment of hypercholesterolemic-induced aortic valve sclerosis
Hamilton, A. M., Boughner, D. R., Drangova, M., & Rogers, K. A. (2010) · Cardiovascular Pathology · doi:10.1016/j.carpath.2010.01.004 · Cited by 19
Habib, M., Thawabi, M., Hawatmeh, A., Habib, H., Elkhalili, W., Shamoon, F. E., & Zaher, M. F. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.03.01 · Cited by 19
Michos, E. D., Narla, V., Blaha, M. J., & Blumenthal, R. S. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6412 · Cited by 19
Colli, A., Gherli, T., Mestres, C. A., & Pomar, J. L. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.03.047 · Cited by 19
Galli, D., Manuguerra, R., Monaco, R., Manotti, L., Goldoni, M., Becchi, G., Carubbi, C., Vignali, G., Cucurachi, N., Gherli, T., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.180 · Cited by 20
Molecular Basis of Cardiovascular Disease
Gotlieb, A. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00014-6 · Cited by 19
Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis
Trenkwalder, T., Nelson, C. P., Musameh, M. D., Mordi, I. R., Kessler, T., Pellegrini, C., Debiec, R., Rheude, T., Lazovic, V., Zeng, L., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.094 · Cited by 18
State of the art paper Lipid-lowering therapy in older persons
Aronow, W. S. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.48148 · Cited by 18
Harnessing Mechanosensation in Next Generation Cardiovascular Tissue Engineering
Garoffolo, G., Ferrari, S., Rizzi, S., Barbuto, M., Bernava, G., & Pesce, M. (2020) · Biomolecules · doi:10.3390/biom10101419 · Cited by 18
Xia, C., Lei, W., Hu, Y., Yang, H., Zeng, X., & Chen, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac016 · Cited by 19
Molnár, A., Pásztor, D. T., & Merkely, B. P. (2022) · Cells · doi:10.3390/cells11213389 · Cited by 18
Yamamoto, K., Yamamoto, H., Takeuchi, M., Kisanuki, A., Akasaka, T., Ohte, N., Hirano, Y., Yoshida, K., Nakatani, S., Takeda, Y., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0499 · Cited by 18
Inhibition of Aortic Valve Calcification by Local Delivery of Zoledronic Acid—an Experimental Study
Synetos, A. G., Toutouzas, K. P., Drakopoulou, M. I., Koutagiar, I. P., Benetos, G., Kotronias, R. A., Anousakis‐Vlachochristou, N., Latsios, G., Καρανάσος, Α., Agrogiannis, G. D., et al. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9802-4 · Cited by 18
The Year in Valvular Heart Disease
Rahimtoola, S. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.023 · Cited by 18
Aortic Stenosis: New Insights in Diagnosis, Treatment, and Prevention
Ito, S., & Oh, J. K. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2022.0234 · Cited by 18
Goland, S., Trento, A., Czer, L. S. C., Eshaghian, S., Tolstrup, K., Naqvi, T. Z., Robertis, M. A. D., Mirocha, J., Iida, K., & Siegel, R. J. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.08.025 · Cited by 18
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Cited by 17
Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients – Where is the Evidence?
Harky, A., Suen, M. M. Y., Wong, C. H. M., Maalik, A. R., & Bashir, M. (2019) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2018-0374 · Cited by 17
Identification of key genes in calcific aortic valve disease by integrated bioinformatics analysis
Teng, P., Xu, X., Ni, C., Yan, H., Sun, Q., Zhang, E., & Ni, Y. (2020) · Medicine · doi:10.1097/md.0000000000021286 · Cited by 17
Increased Ca2+ influx through CaV1.2 drives aortic valve calcification
Matsui, M., Bouchareb, R., Storto, M., Hussain, Y., Gregg, A., Marx, S. O., & Pitt, G. S. (2022) · JCI Insight · doi:10.1172/jci.insight.155569 · Cited by 17
Muddy waters: more stormy SEAS for ezetimibe
Wierzbicki, A. S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01888.x · Cited by 17
Metadata
- Authors
- Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A.
- Affiliations
- Edinburgh Royal Infirmary (GB)
- University of Edinburgh (GB)
- Borders General Hospital (GB)
- Western General Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-09
- Volume
- 352
- Issue
- 23
- Pages
- 2389-2397
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117330772
- Cited by
- 1,146
- References
- 41
- Citations by year
- 2026: 46 · 2025: 52 · 2024: 57 · 2023: 37 · 2022: 47 · 2021: 44 · 2020: 59 · 2019: 38 · 2018: 39 · 2017: 52 · 2016: 52 · 2015: 37 · 2014: 65 · 2013: 64 · 2012: 55
- FWCI
- 47.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- calcific aortic stenosis, atorvastatin, statin therapy, lipid-lowering therapy, valve calcification, disease progression, aortic jet velocity, aortic valve calcium score, LDL cholesterol, hypercholesterolemia, atherosclerosis, echocardiography, CT angiography
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, Aortic Valve, Aortic Valve Stenosis, Blood Flow Velocity, Calcinosis, Double-Blind Method, Heptanoic Acids, Humans, Cholesterol, LDL, Pyrroles, Echocardiography, Doppler, Treatment Failure, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
